zdorПроблемы здоровья и экологииHealth and Ecology Issues2220-09672708-6011Gomel State Medical University10.51523/2708-6011.2021-18-2-12zdor-1945Research ArticleКЛИНИЧЕСКАЯ МЕДИЦИНАCLINICAL MEDICINEЗначимость цистатина С в ранней диагностике диабетической нефропатииDiagnostic value of cystatin C for the early diagnosis of diabetic nephropathyhttps://orcid.org/0000-0002-6956-9014ВасильковаО. Н.VasilkovaV. N.

Василькова Ольга Николаевна, к.м.н., доцент кафедры внутренних болезней № 1 с курсом эндокринологии

Гомель

Volha N. Vasilkova, PhD (Med), Associate Professor at the Department of Internal Diseases No. 1 with the course of Endocrinology

Gomel

olga.n.vasilkova@gmail.comhttps://orcid.org/0000-0001-8529-3890ПчелинИ. Ю.PchelinI. Yu.

Пчелин Иван Юрьевич, к.м.н., доцент, выполняющий лечебную работу кафедры факультетской терапии

Санкт-Петербург

Ivan Yu. Pchelin, PhD (Med), Associate Professor performing clinical work at the Department of Faculty Therapy

Saint Petersburg

ewan2008@bk.ruhttps://orcid.org/0000-0001-9991-044XНауменкоЕ. П.NaumenkaE. P.

Науменко Елена Петровна, врач функциональной диагностики

Гомель

Elena P. Naumenka, physician of functional diagnostics

Gomel

elena.naumenko-72@tut.byhttps://orcid.org/0000-0001-8884-1637БоровецЯ. А.BorovetsYa. A.

Боровец Яна Анатольевна, ассистент кафедры внутренних болезней № 1 с курсом эндокринологии

Гомель

Yana A. Borovets, Assistant Lecturer at the Department of Internal Diseases No. 1 with the course of Endocrinology

Gomel

yana.gh.l.br@gmail.comhttps://orcid.org/0000-0001-8879-5079ЯрецЮ. И.YaretsYu. I.

Ярец Юлия Игоревна, к.м.н., доцент, заведующий клинико-диагностической лабораторией

Гомель

Yulia I. Yarets, PhD (Med), Associate Professor, Head of the Clinical Diagnostic Laboratory

Gomel

artyut@mail.ruhttps://orcid.org/0000-0002-7741-2367КоротаеваЛ. Е.KorotaevaL. E.

Коротаева Людмила Евгеньевна, врач-лаборант лаборатории клеточных технологий

Гомель

Ludmila E. Korotaeva, laboratory physician at the Cell Technologies Laboratory

Gomel

ludmila-79@inbox.ruhttps://orcid.org/0000-0002-9740-9915ВасюхинаИ. А.VasukhinaI. A.

Васюхина Ирина Александровна, врачэндокринолог

Гомель

Irina A. Vasukhina, endocrinologist

Gomel

vasyhina20081978@gmail.comhttps://orcid.org/0000-0002-5040-3460МохортТ. В.MokhortT. V.

Мохорт Татьяна Вячеславовна, д.м.н., профессор, заведующий кафедрой эндокринологии

Минск

Tatsiana V. Mokhort, DMedSc, Professor, Head of the Department of Endocrinology

Minsk

tatsianamokhort@gmail.comГомельский государственный медицинский университетGomel State Medical UniversityСанкт-Петербургский государственный университетSaint Petersburg State UniversityРеспубликанский научно-практический центр радиационной медицины и экологии человекаRepublican Scientific and Practical Center for Radiation Medicine and Human EcologyБелорусский государственный медицинский университетBelarusian State Medical University2021300620211827985Copyright © Василькова О.Н., Пчелин И.Ю., Науменко Е.П., Боровец Я.А., Ярец Ю.И., Коротаева Л.Е., Васюхина И.А., Мохорт Т.В., 20212021Василькова О.Н., Пчелин И.Ю., Науменко Е.П., Боровец Я.А., Ярец Ю.И., Коротаева Л.Е., Васюхина И.А., Мохорт Т.В.Vasilkova V.N., Pchelin I.Y., Naumenka E.P., Borovets Y.A., Yarets Y.I., Korotaeva L.E., Vasukhina I.A., Mokhort T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.gsmu.by/jour/article/view/1945Цель исследования

Цель исследования: оценить клиническую значимость цистатина С в ранней диагностике диабетической нефропатии.

Материалы и методы

Материалы и методы. Обследовано 449 пациентов с сахарным диабетом (СД) 1 и 2 типа в возрасте старше 25 лет. Лабораторное обследование пациентов включало определение в сыворотке крови цистатина С, креатинина, расчет скорости клубочковой фильтрации (СКФ) по формуле CKD-EPI, определение уровня альбуминурии.

Результаты

Результаты. Продемонстрирована роль цистатина С в качестве надежного маркера диабетической нефропатии: уровень цистатина С ≥0,72 мг/л с чувствительностью 90,8 %, специфичностью 88,9% ассоциировался с начинающейся нефропатией при СД (ROC AUC = 0,951).

Заключение

Заключение. Определение уровня цистатина С — одного или совместно с креатинином — поможет более точной диагностике СКФ и оценке риска развития смертности и почечных событий у пациентов с СД.

Objective

Objective: to assess the clinical significance of cystatin C in the early diagnosis of diabetic nephropathy.

Materials and methods

Materials and methods. We examined 449 patients with type 1 and type 2 diabetes mellitusolder than 25 years. The laboratory examination of the patients included the measurement of cystatin, creatinine in the blood serum, GFR calculation according to the CKD-EPI equation, and the determination of albuminuria levels.

Results

Results. The role of cystatin C as a reliable marker of diabetic nephropathy has been demonstrated: the level of cystatin C ≥ 0.72 mg/L with sensitivity of 90.8 %, specificity of 88.9 %, was associated with a decline of renal function in the diabetic patients (ROC AUC = 0.951).

Conclusion

Conclusion. The determination of the level of cystatin C, alone or in conjunction with creatinine, will help to more accurately diagnose GFR and assess the risk of mortality and renal complications in patients with diabetes mellitus.

сахарный диабетдиабетическая нефропатияцистатин Сdiabetes mellitusdiabetic nephropathycystatin CРабота выполнена в рамках научно-исследовательской работы по договору с Белорусским республиканским фондом фундаментальных исследований (БРФФИ) № М17РМ-113 от 01.06.2017 г. и при финансовой поддержке Российского фонда фундаментальных исследований (РФФИ) в рамках проекта 17-54-04080.This study was supported by the Belarusian Foundation for Basic Research (BFBR) (research project No. М17РМ-113) and Russian Foundation for Basic Research (RFBR) (research project No.17-54-04080).ReferencesŻyłka A, Dumnicka P, Kuśnierz-Cabala B, Gala-Błądzińska A, Ceranowicz P, Kucharz J, Ząbek-Adamska A, Maziarz B, Drożdż R, Kuźniewski M. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators Inflamm. 2018;9:7659243. https://doi.org/10.1155/2018/7659243Żyłka A, Dumnicka P, Kuśnierz-Cabala B, Gala-Błądzińska A, Ceranowicz P, Kucharz J, Ząbek-Adamska A, Maziarz B, Drożdż R, Kuźniewski M. Markers of Glomerular and Tubular Damage in the Early Stage of Kidney Disease in Type 2 Diabetic Patients. Mediators Inflamm. 2018;9:7659243. https://doi.org/10.1155/2018/7659243Satirapoj B, Pooluea P, Nata N, Supasyndh O. Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: A prospective cohort study. J Diabetes Complications. 2019 Sep;33(9):675–681. https://doi.org/10.1016/j.jdiacomp.2019.05.013Satirapoj B, Pooluea P, Nata N, Supasyndh O. Urinary biomarkers of tubular injury to predict renal progression and end stage renal disease in type 2 diabetes mellitus with advanced nephropathy: A prospective cohort study. J Diabetes Complications. 2019 Sep;33(9):675–681. https://doi.org/10.1016/j.jdiacomp.2019.05.013Hill NR, Fatoba ST, Oke JL, Hirst JA, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https://doi.org/10.5061/dryad.3s7rdHill NR, Fatoba ST, Oke JL, Hirst JA, et al. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PLoS One. 2016;11(7):e0158765. https://doi.org/10.5061/dryad.3s7rdGansevoort RT, Correa-RotterR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet. 2013;382(9889):339-352. https://doi.org/10.1016/S0140-6736(13)60595-4Gansevoort RT, Correa-RotterR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. The Lancet. 2013;382(9889):339–352. https://doi.org/10.1016/S0140-6736(13)60595-4Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56–61. https://doi.org/10.1136/heartasia-2016-010809Subbiah AK, Chhabra YK, Mahajan S. Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup. Heart Asia. 2016;8(2):56–61. https://doi.org/10.1136/heartasia-2016-010809Siddiqi Z, Karoli R, Kaul A, Fatima J, Varshney S, Beg MS. Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy. Ann Afr Med. 2017;16(3):101–106. https://doi.org/10.4103/aam.aam_12_17Siddiqi Z, Karoli R, Kaul A, Fatima J, Varshney S, Beg MS. Evaluation of neutrophil gelatinase-associated lipocalin and cystatin C as early markers of diabetic nephropathy. Ann Afr Med. 2017;16(3):101–106. https://doi.org/10.4103/aam.aam_12_17Rotbain Curovic V, Hansen TW, Eickhoff MK, von Scholten BJ, Reinhard H, Jacobsen PK, Persson F, Parving HH, Rossing P. Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. Acta Diabetol. 2018;55(11):1143–1150. https://doi.org/10.1007/s00592-018-1205-0Rotbain Curovic V, Hansen TW, Eickhoff MK, von Scholten BJ, Reinhard H, Jacobsen PK, Persson F, Parving HH, Rossing P. Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients. Acta Diabetol. 2018;55(11):1143–1150. https://doi.org/10.1007/s00592-018-1205-0Vijay S, Hamide A, Senthilkumar GP, Mehalingam V. Utility of urinary biomarkers as a diagnostic tool for early diabetic nephropathy in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2018 Sep;12(5):649–652. https://doi.org/10.1016/j.dsx.2018.04.017Vijay S, Hamide A, Senthilkumar GP, Mehalingam V. Utility of urinary biomarkers as a diagnostic tool for early diabetic nephropathy in patients with type 2 diabetes mellitus. Diabetes Metab Syndr. 2018 Sep;12(5):649-652. https://doi.org/10.1016/j.dsx.2018.04.017Willems D, Wolff F, Mekhali F, et al. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem. 2009;2(1-2):108–110. https://doi.org/10.1016/j.clinbiochem.2008.10.002Willems D, Wolff F, Mekhali F, et al. Cystatin C for early detection of renal impairment in diabetes. Clin Biochem. 2009;2(1-2):108-110. https://doi.org/10.1016/j.clinbiochem.2008.10.002Kravaritou M, Thanopoulou A, Karamanos B, et al. Evidence that even “normal” albuminuria may denote incipient GFR reduction in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;85(3):317–321. https://doi.org/10.1016/j.diabres.2009.06.019Kravaritou M, Thanopoulou A, Karamanos B, et al. Evidence that even “normal” albuminuria may denote incipient GFR reduction in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2009;85(3):317–321. https://doi.org/10.1016/j.diabres.2009.06.019Elsayed MS, El Badawy A, Ahmed A, Omar R, Mohamed A. Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(1):374–381. https://doi.org/10.1016/j.dsx.2018.08.017Elsayed MS, El Badawy A, Ahmed A, Omar R, Mohamed A. Serum cystatin C as an indicator for early detection of diabetic nephropathy in type 2 diabetes mellitus. Diabetes Metab Syndr. 2019;13(1):374–381. https://doi.org/10.1016/j.dsx.2018.08.017Arceo ES, Dizon GA, Tiongco REG. Serum cystatin C as an early marker of nephropathy among type 2 diabetics: A meta-analysis. Diabetes Metab Syndr. 2019;13(6):3093– 3097. https://doi.org/10.1016/j.dsx.2019.11.007Arceo ES, Dizon GA, Tiongco REG. Serum cystatin C as an early marker of nephropathy among type 2 diabetics: A meta-analysis. Diabetes Metab Syndr. 2019;13(6):3093– 3097. https://doi.org/10.1016/j.dsx.2019.11.007Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis. 2001;38(2):310–316. https://doi.org/10.1053/ajkd.2001.26096Oddoze C, Morange S, Portugal H, Berland Y, Dussol B. Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis. 2001;38(2):310–316. https://doi.org/10.1053/ajkd.2001.26096Li HX, Xu GB, Wang XJ, Zhang XC, Yang JM. Diagnostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. Chin Med J (Engl). 2010 Mar 20;123(6):745–751.nostic accuracy of various glomerular filtration rates estimating equations in patients with chronic kidney disease and diabetes. Chin Med J (Engl). 2010 Mar 20;123(6):745–751.Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007 Mar;53(3):480–488. https://doi.org/10.1373/clinchem.2006.076042Pucci L, Triscornia S, Lucchesi D, et al. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem. 2007 Mar;53(3):480–488. https://doi.org/10.1373/clinchem.2006.076042

The authors declare that there are no conflicts of interest present.